Circulating Biomarker Market Report 2025 (Global Edition)

Global Circulating Biomarker Market Report 2025 Market Size Split by Product (Circulating DNA, Circulating Tumour Cells, Others), by End User (Hospitals, Medical Research Centre, Others)

Circulating Biomarker Market Report Description

We have various report editions of Circulating Biomarker Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Circulating Biomarker Market Insights Video

Competitive Landscape of the Circulating biomarker Market

The competitive landscape of the circulating biomarker market is characterized by intense research and development activities aimed at discovering novel biomarkers and advancing diagnostic technologies. Key players focus on expanding their product portfolios through strategic collaborations, acquisitions, and partnerships with academic institutions and research organizations. Innovation in molecular biology and bioinformatics drives differentiation, while regulatory compliance and market approval play pivotal roles in market entry. Continuous advancements in technology and a growing emphasis on personalized medicine further shape the competitive dynamics of the market.

For instance, in March 2022, Agilent launched a Center for Excellence (CoE) laboratory facility at Gujarat Technological University (GTU). This collaborative space will be accessible to GTU faculty, students, and Agilent teams, facilitating the exploration and development of innovative application workflows in analytical chemistry, biopharmaceuticals, and life sciences research. Designed as a shared hub for education and research, the new CoE instrumentation lab aims to foster significant scientific breakthroughs and validations. It will also function as a vital technological resource for academia, providing extensive opportunities to advance research capabilities and drive impactful discoveries in these critical fields. (Source: https://www.agilent.com/about/newsroom/presrel/2022/15mar-ah-22009.html#:~:text=Agilent%20India%20also%20achieved%20a,on%2014th%20March%202022.)

Top Companies Market Share in Circulating Biomarker Industry: (In no particular order of Rank)

• GE Healthcare
• Agilent Technologies
• Epigenomics AG
• Fluxion Biosciences
• Affymetrix
• BD
• Abbott Laboratories
• Biocept
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Circulating biomarker Market

Which Region Dominates the Circulating biomarker Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 due to several factors. Firstly, robust healthcare infrastructure and high healthcare expenditure support the adoption of advanced diagnostic technologies like circulating biomarkers. Secondly, a large patient pool suffering from chronic diseases drives demand for early detection and personalized medicine solutions. Additionally, strong emphasis on research and development fosters continuous innovation in biomarker discovery and validation. Moreover, favorable regulatory policies and reimbursement frameworks facilitate market penetration and commercialization of biomarker-based tests, further bolstering growth in the region.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Circulating biomarker market due to expanding healthcare infrastructure and increasing healthcare investments across countries like China, India, and Japan. Rapid urbanization and lifestyle changes contribute to a rising prevalence of chronic diseases, boosting demand for innovative diagnostic tools like biomarkers. Furthermore, advancements in healthcare technology and growing awareness among healthcare providers and patients drive adoption rates. Moreover, government initiatives to improve healthcare access and affordability are propelling market growth. The region's diverse patient demographics and large untapped market potential make it a lucrative growth opportunity for biomarker manufacturers and developers.

 

The current report Scope analyzes Circulating Biomarker Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Circulating Biomarker

According to Cognitive Market Research, the global circulating biomarker market size was estimated at USD XX Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.

• According to Cognitive Market Research, The United States circulating biomarker market had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. In the U.S., sales of circulating biomarkers will increase due to robust healthcare infrastructure, high prevalence of chronic diseases, and strong investments in research and development, fostering innovation and adoption.
Canada had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period. In Canada, increasing healthcare expenditure, a growing aging population, and advanced diagnostic capabilities drive demand for circulating biomarkers, supporting market growth. Mexico had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period.

Europe Circulating Biomarker

According to Cognitive Market Research, the global Circulating biomarker market size was estimated at USD XX Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031

• The United Kingdom circulating biomarker market had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.8% during the forecast period. In the UK, rising awareness of personalized medicine, stringent regulatory standards, and a focus on early disease detection enhance the adoption of circulating biomarker technologies, driving market expansion.
France had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.2% during the forecast period. Germany had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period. Germany's market growth in circulating biomarkers is propelled by its leadership in biomedical research, technological advancements in healthcare, and a proactive approach to integrating innovative diagnostic tools into clinical practice. Italy had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.4% during the forecast period. Russia had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. Spain had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period. Luxembourg had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.1% during the forecast period. Portugal had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. Greece had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. Rest of Europe had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period.

Asia Pacific Circulating Biomarker

According to Cognitive Market Research, the global Circulating biomarker market size was estimated at USD XX Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.

• According to Cognitive Market Research, China had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 13.0% during the forecast period. In China, rapid urbanization, increasing healthcare investments, and government initiatives promoting precision medicine contribute to the rising adoption of circulating biomarkers for disease diagnosis and management.
Japan had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 12.0% during the forecast period. India had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 15.3% during the forecast period. India sees increasing sales of circulating biomarkers due to a large patient population, rising burden of chronic diseases, and advancements in healthcare infrastructure, driving demand for advanced diagnostic solutions. South Korea had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 12.6% during the forecast period. Australia had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 13.2% during the forecast period. South East Asia had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 14.5% during the forecast period. Rest of Asia Pacific had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 13.3% during the forecast period.

South America Circulating Biomarker

According to Cognitive Market Research, the global Circulating biomarker market size was estimated at USD XX Million out of which Latin America market of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.

• According to Cognitive Market Research, Brazil had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 11.5% during the forecast period. Brazil experiences growth in circulating biomarker sales due to expanding healthcare access, rising incidence of cancer and cardiovascular diseases, and government initiatives supporting healthcare innovation and research.
Argentina had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. In Argentina, increasing awareness of early disease detection, adoption of advanced diagnostic technologies, and healthcare infrastructure development fuel demand for circulating biomarkers. Colombia had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period. Peru had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 11.1% during the forecast period. Chile had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 11.2% during the forecast period. Rest of Latin America had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.0% during the forecast period.

Middle East and Africa Circulating Biomarker

According to Cognitive Market Research, the global circulating biomarker market size was estimated at USD XX Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.

• GCC Countries had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 12.0% during the forecast period. GCC Countries witness growing sales of circulating biomarkers driven by high healthcare expenditure, rising prevalence of lifestyle-related diseases, and government initiatives promoting healthcare innovation and technology adoption.
Egypt had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 11.5% during the forecast period. South Africa had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 12.2% during the forecast period. South Africa's market for circulating biomarkers grows due to improving healthcare infrastructure, rising chronic disease prevalence, and increasing investment in medical research and diagnostic technologies. Turkey had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period. Nigeria had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. Rest of MEA had a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period.

Circulating Biomarker Market Analysis

Circulating biomarker Market Product Segment Analysis

According to Cognitive Market Research, circulating circulating tumour cells stands out as the dominating category due to their critical role in cancer management, offering real-time insights into disease progression and treatment response. The demand is driven by the increasing incidence of cancer globally and the need for personalized treatment strategies. Technological advancements in capturing and analyzing rare circulating tumor cells enhance diagnostic accuracy and therapeutic monitoring, further boosting market growth.

Circulating DNA emerges as the fastest-growing category in the circulating biomarker market owing to its non-invasive nature and broad applicability across various diseases. The rising adoption of liquid biopsy techniques for cancer detection fuels demand. Additionally, advancements in sequencing technologies and bioinformatics facilitate the detection of genetic mutations and alterations associated with disease, driving diagnostic accuracy and clinical utility. Moreover, the potential for early detection of diseases and monitoring treatment responses propels the rapid growth of circulating DNA biomarkers in clinical settings.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Circulating Biomarker Industry. Request a Free Sample PDF!

Circulating biomarker Market End User Segment Analysis

According to Cognitive Market Research, the dominating category is hospitals due to their central role in patient care and diagnostics. Hospitals benefit from the need for routine diagnostic testing and the integration of advanced technologies for disease management. Additionally, their capacity for large-scale patient interaction and treatment facilitates the adoption of biomarker-based tests, supporting market dominance.

The fastest-growing category in the circulating biomarker market is medical research centre owing to their pivotal role in biomarker discovery and validation. These centers drive innovation through extensive research efforts, collaborating with academia and industry to develop new biomarkers and improve diagnostic capabilities. Furthermore, increasing investments in biomedical research and clinical trials enhance the demand for biomarkers, positioning medical research centers at the forefront of market growth. Their focus on advancing scientific knowledge and translating findings into clinical applications accelerates adoption rates in healthcare settings.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Vinayak Bali

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

Catering to tailored needs of clients in Consulting, Business Intelligence, Market Research, Forecasting, Matrix-Modelling, Data Analytics, Competitive Intelligence, Primary research and Consumer Insights.

Author's Conclusion